IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pharmacological autophagy enhancement constitutes a preclinically validated strategy for preventing or treating most major age-associated diseases. Driven by this consideration, we performed a high-content/high-throughput screen on 65 000 distinct compounds on a robotized fluorescence microscopy platform to identify novel autophagy inducers. RESULTS: Here, we report the discovery of picropodophyllin (PPP) as a potent inducer of autophagic flux that acts on-target, as an inhibitor of the tyrosine kinase activity of the insulin-like growth factor-1 receptor (IGF1R). Thus, PPP lost its autophagy-stimulatory activity in cells engineered to lack IGF1R or to express a constitutively active AKT serine/threonine kinase 1 (AKT1) mutant. When administered to cancer-bearing mice, PPP improved the therapeutic efficacy of chemoimmunotherapy with a combination of immunogenic cytotoxicants and programmed cell death 1 (PDCD1, better known as PD-1) blockade. These PPP effects were lost when tumors were rendered PPP-insensitive or autophagy-incompetent. In combination with chemotherapy, PPP enhanced the infiltration of tumors by cytotoxic T lymphocytes, while reducing regulatory T cells. In human triple-negative breast cancer patients, the activating phosphorylation of IGF1R correlated with inhibited autophagy, an unfavorable local immune profile, and poor prognosis. CONCLUSION: Altogether, these results suggest that IGF1R may constitute a novel and druggable therapeutic target for the treatment of cancer in conjunction with chemoimmunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, pharmacological inhibition of IGF1R improves anticancer immunosurveillance, 217”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [217]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, enzymatic inhibition of IGF1R with tyrosine kinase inhibitors improves anticancer immunosurveillance requiring autophagy induction in malignant cells 142 .”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Self-citationExtending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Self-citationAutophagy modulation as a potential therapeutic target for diverse diseases
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3802 · Cited by 1,437 · cited 1×
“5 6 In the context of cancer, autophagy plays an ambiguous role.”
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Self-citationVarghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Self-citationMetabolic control of autophagy
Galluzzi, L., Pietrocola, F., Levine, B., & Kroemer, G. (2014) · Cell · doi:10.1016/j.cell.2014.11.006 · Cited by 855
Self-citationRecent insights into the function of autophagy in cancer
Amaravadi, R., Kimmelman, A. C., & White, E. (2016) · Genes & Development · doi:10.1101/gad.287524.116 · Cited by 813
Cited by
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Self-citationThe hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
“In line with this notion, autophagy inhibition downstream of insulin-like growth factor 1 receptor (IGF1R) hyperactivation is a poor prognostic marker coupled with signs of deficient immunosurveillance in breast cancer 130 .”
Self-citationMeta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Self-citationDietary regulation in health and disease
Wu, Q., Gao, Z.-J., Yu, X., & Wang, P. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01104-w · Cited by 176
Self-citation
Metadata
- Authors
- Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., Zhang, S., Hui, P., Madeo, F., Tu, Y., Kepp, O., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Renmin Hospital of Wuhan University (CN)
- Samsara Therapeutics Ltd, Oxford, UK
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France
- University of Graz (AT)
- Karolinska University Hospital (SE)
- Corresponding author
- Tu, Yi
- Kepp, Oliver
- Kroemer, Guido
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-06
- Volume
- 9
- Issue
- 6
- Pages
- e002722
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8204183
- OpenAlex
- W3166418545
- Cited by
- 83
- References
- 64
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 17 · 2023: 16 · 2022: 20 · 2021: 5
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Association pour la recherche sur le cancer
- BioTechMed
- University of Graz (Fast4Health)
- Université Paris-Saclay, Plateforme Imagerie
- Île de France (DIM Elicit)
- Ligue Contre le Cancer
- Natural Science Foundation of Hubei Province (2020CFA026)
- Agence National de la Recherche (Projets blancs)
- European Union
- Fondation pour la Recherche Médicale
- High-end Foreign Expert Program in China (GDW20171100085)
- Fondation Carrefour
- IdEx Université de Paris ANR (18-IDEX-0001)
- Labex (ANR-18-IDEX-0001)
- Austrian Federal Ministry of Education, Science and Research (BMWFW-80.109/0001-WF/V/3b/2015))
- Austrian Science Fund (W1226, P27893, P29203,P29262,P31727, SFB LIPOTOX F3007 & F3012)
- Chinese Scholarship Council
- AMMICa (US23/CNRS UMS3655)
- Association Ruban Rose
- Canceropôle Île de France
- Elior
- Equipex Onco-Pheno-Screen
- European Joint Program on Rare Disease
- Gustave Roussy (Odyssea)
- European Union Horizon 2020 Projects (Oncobiome and Crimson)
- Institut National Du Cancer
- INSERM
- Institut Universitaire de France
- RHU Torino Lumière
- Seerave Foundation
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
- SIRIC Cancer Research and Personalized Medicine
- NAWI Granz (BioHealth)
- BioTechMed-Graz (EPIAge)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- IGF-1 receptor, picropodophyllin, autophagy, AKT1, chemoimmunotherapy, anti-PD-1 therapy, regulatory T cells, triple-negative breast cancer, combination cancer therapy, autophagy enhancers
- MeSH terms
- Animals, Antineoplastic Agents, Autophagy, Female, Humans, Receptor, IGF Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. https://app.cochat.ai/papers/10.1136/jitc-2021-002722
- The paper
- Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., Zhang, S., Hui, P., Madeo, F., Tu, Y., Kepp, O., & Kroemer, G. (2021). IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.